Although high affinity BCL-2 antagonists such as ABT-737/ABT-263 hold considerable promise for cancer therapy, complex factors dictate whether an individual tumor is likely to respond to treatment, including the levels and bound state of multiple anti- and pro-apoptotic BCL-2 family proteins [21]. Here, BCL2 is linked to cancer.